{"name":"Astex Pharmaceuticals, Inc.","slug":"astex-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"Pleasanton","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Treatment Choice (TC)","genericName":"Treatment Choice (TC)","slug":"treatment-choice-tc","indication":"Relapsed or refractory acute myeloid leukemia (AML)","status":"phase_3"},{"name":"Decitabine/Cedazuridine","genericName":"Decitabine/Cedazuridine","slug":"decitabine-cedazuridine","indication":"Myelodysplastic syndromes (MDS)","status":"phase_3"},{"name":"AT13387 and Imatinib","genericName":"AT13387 and Imatinib","slug":"at13387-and-imatinib","indication":"Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL)","status":"phase_2"},{"name":"AT7519M","genericName":"AT7519M","slug":"at7519m","indication":"Myeloproliferative neoplasms","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Treatment Choice","genericName":"Treatment Choice","slug":"treatment-choice","indication":"Other","status":"marketed"},{"name":"ASTX727 Dose Confirmation","genericName":"ASTX727 Dose Confirmation","slug":"astx727-dose-confirmation","indication":"Other","status":"phase_1"},{"name":"ASTX727 Dose Escalation","genericName":"ASTX727 Dose Escalation","slug":"astx727-dose-escalation","indication":"Other","status":"phase_1"},{"name":"ASTX727 Fixed-Dose Combination","genericName":"ASTX727 Fixed-Dose Combination","slug":"astx727-fixed-dose-combination","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Treatment Choice (TC)","genericName":"Treatment Choice (TC)","slug":"treatment-choice-tc","phase":"phase_3","mechanism":"Treatment Choice (TC) is a small molecule that targets the CD47/SIRPα axis.","indications":["Relapsed or refractory acute myeloid leukemia (AML)"],"catalyst":""},{"name":"Decitabine/Cedazuridine","genericName":"Decitabine/Cedazuridine","slug":"decitabine-cedazuridine","phase":"phase_3","mechanism":"Decitabine is a DNA methyltransferase inhibitor that causes hypomethylation of DNA, leading to reactivation of silenced tumor suppressor genes and differentiation of myelodysplastic cells.","indications":["Myelodysplastic syndromes (MDS)","Acute myeloid leukemia (AML)"],"catalyst":""},{"name":"Treatment Choice","genericName":"Treatment Choice","slug":"treatment-choice","phase":"marketed","mechanism":"DNA repair enzyme","indications":[],"catalyst":""},{"name":"ASTX727 Dose Confirmation","genericName":"ASTX727 Dose Confirmation","slug":"astx727-dose-confirmation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASTX727 Dose Escalation","genericName":"ASTX727 Dose Escalation","slug":"astx727-dose-escalation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASTX727 Fixed-Dose Combination","genericName":"ASTX727 Fixed-Dose Combination","slug":"astx727-fixed-dose-combination","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT13387 and Imatinib","genericName":"AT13387 and Imatinib","slug":"at13387-and-imatinib","phase":"phase_2","mechanism":"AT13387 is a potent and selective inhibitor of the B-Raf V600E kinase, while Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-Kit, and PDGFR.","indications":["Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL)","Gastrointestinal stromal tumors (GIST)"],"catalyst":""},{"name":"AT7519M","genericName":"AT7519M","slug":"at7519m","phase":"phase_2","mechanism":"AT7519M is a potent inhibitor of the JAK2 protein.","indications":["Myeloproliferative neoplasms"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPVXlPOS00X25mQ0NGUEdfTnZHcjZKYWhlQkZGcllNX09tQUpGdkFhcUZ6OWFMSTA1MW5pdGpZQjdmbEtIVmVBSS1HWVZleWRVZ0s0bGJNYjZmNno5aFFMdEdCZXpHckZDZ3BUODE1UTRxVFRSeUQ1TjlpU2s3R0VUMDZ1ZGJTc0Q0UWJkQUhPUQ?oc=5","date":"2025-11-12","type":"pipeline","source":"Yahoo Finance","summary":"KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight - Yahoo Finance","headline":"KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expandin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNWkpmeDR4WThrOFVCNE1QTVRuZjhQbmptWkZMWDY3VkpLdDJTSWFqeVVPcjgtbkVGZG1acExJT1NlazVFbE1XZE9TMDc3LV92VmcxbzRLUThpNEZSVm1NWFVha0FrNWVXTzZlSTRnVGJwdGJnV255UEM3NWFaMFJHUzVFZlhKam9qazVRbTF0Y3UtWmRtQTZKYVFGUFZLTmZuSWFGdk51MWszUGpw?oc=5","date":"2025-10-02","type":"trial","source":"BioWorld News","summary":"Pharma pools structural data to boost power of AI in drug discovery - BioWorld News","headline":"Pharma pools structural data to boost power of AI in drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOV3JjdUtmekZwbE9EbU5HSVJ0TlJRSGpNbklJZUlFTEg4SEg5Z0liREdYd2tyWHlUYjFQUHZpdjJUNEJjVnJ4Zk5XWkxJSHhmRWlpdFhJTjRFX1VlQUhBaWt5RjQwRUZ0bm9qczNWMmRIVTBESERRb1RJckl1NE9NZVk4aVp0TEZfNmVvTktTblJfY1p6dHRyWkxIc18zWkxVbTdEbWZxS2pQclhJU3lOdkVDRHNCb3FpZjc2MnhkbXdiTDFS?oc=5","date":"2025-10-01","type":"trial","source":"Reuters","summary":"Bristol Myers, Takeda to pool data for AI-based drug discovery - Reuters","headline":"Bristol Myers, Takeda to pool data for AI-based drug discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPV093SXFURVE1Rk9SVGt0SVQ1TVhhMHRxcjhWRXRlYXJIWVJvNFcyNkF2a0h3MDdiOHM5bWVRMjRfbGFWZTFKSk5EdXFSSWtGMVBZRzZra3c1Y05zaWNabDNXME5HZm93MlFpZ1AyZEN2dE00TGVYOTZLRS1jNjNkdm5VWWY5V29HdHc?oc=5","date":"2025-04-25","type":"deal","source":"PharmaTimes","summary":"Mosaic therapeutics expands pipeline with Astex deal - PharmaTimes","headline":"Mosaic therapeutics expands pipeline with Astex deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxQckg3T1duZlh2bXZNNnAzYXlMdkNkcUV2YXA4c2RvUFNhTW5iY3lZSmx5WXUwXzBlTTJ1eWZINW1yeFk4WlZId0haMkpUWXF0M204SzkzeE10UW9acDdWY3Q1dmQ3T0xjc0RkeUV2RzdqWEJwdVFVeTFGRFF0VS1oczVnYU1iODZIU21ORURpZlB5Q2hSSTJKLU5vcTMyOVpXQ1QwWGNWR1RTbTJXNm5xMGMwbUR3YV9hQi1LOWJJMUN1Y0xiZURpelg4SWZ0RXlfdkhrR0VnZFp1MzFFVFFNU3J5eTZVTjJnQ2ctSkRmOU5WQlprR3p4WHltSi1VUjA2UlZxZUJwOTVPMnNodGlmQndFZ0g2endieEJyYlgyMnJ3Q2k4czRVaHBpbVhUdw?oc=5","date":"2025-04-24","type":"deal","source":"businesswire.com","summary":"Mosaic Therapeutics In-Licenses Two Clinical-Stage Oncology Programs From Astex Pharmaceuticals for Development as Proprietary Combination Therapies - businesswire.com","headline":"Mosaic Therapeutics In-Licenses Two Clinical-Stage Oncology Programs From Astex Pharmaceuticals for Development as Propr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWnJoNTByeGo4LV84eEVaRV91cFNtTXlPd1J0ajYxcG9GNzBhQnpDN0RBUkNGYnpob1RRRFREMzZQa0pLUDNDZ1ktckhUOE5qcXREckNtN0pVaEFrZF9hdGlqUXY1cXQ5Tkp2VVZPcnRSOXExUDlTTXJCT2c5TXYyUDZ5MnZGOE1pNzctMlM2S25JcU1DUmFuVzB4TGJPUUFMVUZZSXpiYk9idw?oc=5","date":"2025-04-24","type":"deal","source":"Contract Pharma","summary":"Mosaic Therapeutics In-Licenses Oncology Programs from Astex - Contract Pharma","headline":"Mosaic Therapeutics In-Licenses Oncology Programs from Astex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5ENHFJaVdnVWkyNDJ4WWpVb3NOSzU2YjZsdW5JSEEydWFYd21yV1BHRUpwM2JPOWlZMXlwMTc0RTYtZE9MSXAyYWpSTFBjQkpJRnE4SkxSRGFHcXRfcUQwMzRKRkN1VzhE?oc=5","date":"2024-02-15","type":"pipeline","source":"Wiley Online Library","summary":"Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups - Wiley Online Library","headline":"Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPanlMVEd2N1VVbExrTS02X3h0Z09VSUpvbFozZTJFbGpONVplbS0xRnNoXzZDU1ZlZ1dSZW1CMllpZTlnSEJJeVROU2VEamsyTzE4YWFQUy1wQ2E2b0dLM21sNkVQaU9rMGMxcWRGOXBVRnJYcFI3MGl1cTdreFRlWm5hN0pQcm1VcXFlbXhrQkgtc0VpM2dWQ0tnZmdheU51WU1QUGU4NXhlMGYyYWdCMUc2eWRHbnl4ejM1bGhob0ZKT29pQlBkRlVUSVVvQlpfeWdqbFBGem4yUFBkdk51V0xoZThzaG1wZFlR?oc=5","date":"2023-11-17","type":"trial","source":"prnewswire.com","summary":"Taiho Oncology and Astex Pharmaceuticals Announce Data Presentations at the 65th ASH Annual Meeting - prnewswire.com","headline":"Taiho Oncology and Astex Pharmaceuticals Announce Data Presentations at the 65th ASH Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQUmhYX0pNSkJodGU0NENXd2lDRmxDMVhNSHdnbXF1NzlTQndPdmhpdjZpN0EzaXNWSlVQOVNLQ3M5ek0xUExNVkp4dFVPREEwZDEzTm9fRjA4X0l6UUU4bGZrLW5WRUhONy1KbmhwczItZXN0aHJJUHZmSEE1RXRIc2Z2Y0owV3hXa2JDenJnLXduNTNBc09tWVM0WWRPbjI5SlpZUFJLWVNSa0c4?oc=5","date":"2023-09-21","type":"regulatory","source":"CancerNetwork","summary":"Decitabine/Cedazuridine Earns European Approval in Acute Myeloid Leukemia - CancerNetwork","headline":"Decitabine/Cedazuridine Earns European Approval in Acute Myeloid Leukemia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNaHIwb21falFIWTg0bGd1ZmdlaGdpV1BiM0tfUHpGTWhZMXVuVkt5eGJwN3RRekFnQmh6VnNIXzdGdFFQTFpXU0Q1TmU4WEdQeU9ia0ZCSnNjVDQ0MmpDWHhsTUFUU3FLZFl3RUhmWjVlOWhUazRsZnR3ZXZHTzROMTFmUENVUUlWcU8wckZ2VUowdDNEa3BMQ3Zpb2xTUVlsdUw2ZjFIVnY4UDMyckE?oc=5","date":"2021-03-12","type":"pipeline","source":"Pharmacy Times","summary":"Inqovi From Astex Pharmaceuticals, Otsuka Pharmaceutical, and Taiho Oncology - Pharmacy Times","headline":"Inqovi From Astex Pharmaceuticals, Otsuka Pharmaceutical, and Taiho Oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9fenFYWGxqX0J1eWpGRDBlejlEdmxpWTZlVlhnVVRfdzRTWlhCeUwtdzhNUUFBdVhZVjdVOW9Ia3RYb3VVMVJLbW02VlRxd2VsLVB1R19WNnVYUkI5bkFOZzBucFN6emNhaFZz?oc=5","date":"2020-12-10","type":"pipeline","source":"BioSpace","summary":"BioSpace Movers & Shakers, Dec. 11 - BioSpace","headline":"BioSpace Movers & Shakers, Dec. 11","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPOGlrRi1hcl81LVpPQTY0NnFoQThyS1RFVm9icDU4TlFEakFmaTZhS1lucFJ5T19GZXJJTFFUZTBlVU5FdnZRd0dueG8wOXpaaG4xRmNzS2diWExtSGFGMm5pSW94ckVGcjZYVmkyZjhFOFpCZ3ZacGhzQUNiNFpuX2EyTVVTVVJpVENaX0ZnbTFnWVUwQUpTV1FEQk0teXBpWlBlWGRBSmVYTUJsWmRPcElvMA?oc=5","date":"2013-09-05","type":"deal","source":"RTTNews","summary":"Astex Pharma Agrees To Be Acquired By Japan's Otsuka Pharma For $886 Mln Cash - RTTNews","headline":"Astex Pharma Agrees To Be Acquired By Japan's Otsuka Pharma For $886 Mln Cash","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":2,"marketed":1,"phase_1":3,"phase_2":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}